Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (138612)	5/1/2018 7:01:08 PM
From: Elroy Jetson	Respond to of 217791

The CEO of a biomedical startup who sparked controversy when he injected himself with an untested herpes treatment in front of a live audience in February has died. - livescience.com Aaron Traywick, the CEO of Ascendance Biomedical, was found dead at 11:30 a.m. ET on Sunday (April 29) in a spa room in Washington, D.C., according to a statement provided to Live Science by the Metropolitan Police Department (MPD) of the District of Columbia. Traywick was 28 years old. Traywick was found in a flotation tank. Flotation tanks are soundproof pods filled with body-temperature saltwater that are used to promote " sensory deprivation." The MDP is still investigating Traywick's death, though they note that at this point, they have no evidence suggesting foul play. Traywick made news in October 2017, when he staged a live demonstration of a purported gene-therapy treatment for HIV, Live Science previously reported. The untested treatment was given to a volunteer named Tristan Roberts who has HIV; Roberts said that one month after the injection, his viral load had risen, not fallen. Shortly after that demonstration, the U.S. Food and Drug Administration (FDA) issued a warning about using untested gene therapies, which read, in part, "FDA is aware that gene therapy products intended for self-administration and 'do it yourself' kits to produce therapies for self-administration are being made available to the public. The sale of these products is against the law. FDA is concerned about the safety risks involved." Traywick and Roberts skirted this law, however, through self-experimentation — they weren't selling the products.